Theralase Technologies Inc. V.TLT

Easy to Deliver and Patient Friendly

[enriquesuave]

"Dr. Peter Black, MD, FRCSC, a Urologic Oncologist at Vancouver General Hospital, a Research Scientist at the Vancouver Prostate Centre, and a Professor in the Department of Urologic Sciences at the University of British Columbia stated “I think this is a great opportunity for patients to gain access to a promising new technology and treatment that is easy to deliver and very patient-friendly. We are delighted to be able to offer it to patients in British Columbia.”
If we hit close to 67%  at 12 months or even slightly less, on first 25 patients and other treated patients who have not yet reached 12 months are responding very well to optimized treatment even at 3, 6 or 9 months ( 67% or better), then we may have excellent chances of Accelerated FDA approval IMO. Let's hope they all get it right this time. A simple and patient friendly procedure.

[enriquesuave]

Actually says "Very patient friendly "  as opposed to most of the other competing drugs which are either loaded with fairly severe side effects or many more treatment visits  imo  

[StevenBirch]

There was a TV ad the other night from Bristol Myers Squibb, for lung cancer, about their combination of Opdivo and Yervoy and it listed all the side effects - including death! Given the safety of 'our' treatment how can we not beat the competition? And even if 12 months is the standard how far along the timeline do we need to go to see some serious price appreciation here? Does it start

[CancerSlayer]

If we get approved, there should be an asterisk by TLD-1433. *Approved under extraordinary circumstances...despite application delays, protocol corrections, institutional apathy & a global pandemic, TLT was able to shine over all the rest. Would'nt surprise me if this pandemic has also resulted in the resetting of review boards' & health authorities' thresholds for

[enriquesuave]

Easy to Deliver and Very Patient Friendly.  All we need now is Unparalleled Efficacy and Safety.  Then we can call this the new Gold Standard.  The SP move seen in GLSI , a 24 fold intraday increase becomes possible when data is very significantly better than the competition or standard of care.  Here competition is showing 17-24% CR at 12 months, so with anything significantly

[CancerSlayer]

  And only one competitor that's currently approved (Keytruda) with a marginal 17% durable response.  I'm not sure I can even qualify the competition as "competition".  We currently have no PDT competitor for this indication & we require the fewest treatments.  I think our side effect profile may also be incomparable.  Always like to compare apples

[Longholder99]

Any thougts on what Theralase will charge for the NMIBC treatment?

[newdaydawning]

My recollection from an earlier post is somewhere in the range of US$50K. 

[Longholder99]

Per treatment? Also....would the application of the 'for you, made with your cells' vaccine be an extra charge. Perhaps 50k here....but in the USA the costs could/will be higher IMO. The recurring revs will be a monster. Almost within months after early approval.

[Eoganacht]

Roger Dumoulin-White wrote this in the April 2014 Cantech Letter:   "Annual sales would ramp immediately after commercialization, but assuming a treatment cost of $50,000 per patient with 1000 patients treated annually at each of 50 facilities, gross revenue from the procedures would total $2.5-billion. If Theralase was paid 50% of the gross revenue for the PDC and the laser system

[tamarindo1]

Roger said a lot in 2014.